HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 30, 2018-- Spectrum Pharmaceuticals, Inc.  (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business

An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrum’s current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 2, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

ADVANCE, first Phase 3 study, met the non-inferiority of ROLONTIS to pegfilgrastim endpoint in the Duration of Severe Neutropenia (DSN) across all 4 cycles (all p

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 25, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday,

HENDERSON, Nev. --(BUSINESS WIRE)--May 30, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy

Primary endpoint of non-inferiority of ROLONTIS to pegfilgrastim was met All secondary endpoints were met Adverse events were similar between ROLONTIS and pegfilgrastim ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that utilizes a propriety technology HENDERSON,

HENDERSON, Nev. --(BUSINESS WIRE)--May 9, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy

Enrollment completed in MD Anderson’s 50 patient EGFR exon 20 mutation cohort for poziotinib in non-small cell lung cancer. Nature Medicine publication reported a confirmed objective response rate of 64 percent in the first 11 patients with EGFR exon 20 mutations treated with poziotinib.

HENDERSON, Nev. --(BUSINESS WIRE)--May 3, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The

HENDERSON, Nev. --(BUSINESS WIRE)--May 1, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo

Shareholder Rights Plan Amended to Eliminate Poison Pill Bylaws Amended to Enable Proxy Access and Majority Voting Dr. Bernice R. Welles Recommended to be Added to Spectrum’s Board of Directors HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 30, 2018-- Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 26, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 23, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced a publication entitled, “Mechanisms and

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 17, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced a poster presentation of data from preclinical and

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 10, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that updated poziotinib Phase 2 data in MD

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 3, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 7, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology Company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy

Poziotinib: following promising interim results, the Company is actively enrolling NSCLC patients with exon 20 insertion mutation in a multi-center study. ROLONTIS ™ (eflapegrastim): ADVANCE study recently met the primary efficacy endpoint; RECOVER study fully enrolled; BLA filing expected in Q4